Emerging Challenges: Neurological Manifestations of Systemic Diseases and Medication-Induced Neurological Disorders

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 2651

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Neurology, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
2. Department of Neurology, Clinical Emergency County Hospital, Timisoara, Romania
Interests: evidence-based medicine; movement disorders; cognition; basal ganglia; infectious diseases
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
1. Department of Neurology, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
2. Department of Neurology, Clinical Emergency County Hospital, Timisoara, Romania
Interests: inflammation; epilepsy; movement disorders; evidence-based medicine; infectious diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Neurologic complications of systemic disease include any neurologic disorder caused by a condition that originates outside of the nervous system. The diagnosis of the systemic disease may be well established or unknown when the neurologic complications develop. The pathogeneses for these complications of systemic disease are wide-ranging, although sometimes the underlying pathophysiologic mechanisms remain unclear. The systemic disease may either cause a complication in the nervous system through the same mechanisms as it does in other organs (e.g., inflammation from vasculitis), or the effect on the nervous system may be entirely different from the pathogenesis of the systemic disease (e.g., malabsorption from a gastrointestinal disorder causing the development of a peripheral neuropathy or cognitive impairment).

The range and breadth of diseases of the nervous system caused by immunological, infective, inflammatory, degenerative, or metabolic disturbances are extensive. While neurological symptoms often arise in patients with established diagnoses, it is also possible for a neurological symptom to be the presenting feature of an undiagnosed systemic disorder. It is, therefore, imperative to consider underlying systemic diseases when assessing a patient for neurological complaints, looking for supportive clinical findings, laboratory abnormalities, and imaging features in the appropriate clinical context. These conditions are frequently treatable, and, in some instances, also curable. Therefore, their recognition and treatment impact the outcomes of these patients.

A broad spectrum of neurological presentations may be caused or precipitated by drugs, both prescribed and non-prescribed. This can be at first presentation or in cases with already established neurological disease. Doctors have a responsibility to prevent iatrogenic symptoms by carefully prescribing and identifying drug-induced syndromes. Failure to consider a drug-induced cause may lead to inappropriate investigations and management. Current drugs (prescribed, over the counter, herbal remedies, and drugs of misuse) and how they are taken, drugs tried previously, and the reason for discontinuation, treatment response, adverse effects, allergies, and intolerances should be taken into account. Recent immunizations may also be of importance.

In this Special Issue, we encourage proposals that critically analyze and discuss current knowledge on the neurological manifestations of systemic diseases and medication-induced neurological disorders. We aim to present research and theoretical papers addressing all aspects, from pathophysiologic mechanisms and diagnosis to therapeutic strategies for these neurological conditions. Thus, we invite colleagues working and/or involved in any field to submit their work for publication in this Special Issue. Original papers, as well as reviews, are welcome.

Dr. Elena Cecilia Rosca
Dr. Amalia Cornea
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nervous system
  • neurologic
  • complications
  • systemic
  • medication
  • vaccine
  • side effect

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 575 KiB  
Review
Neurocognitive and Neuropsychiatric Implications of Fibrosing Interstitial Lung Diseases
by Zsolt Vastag, Emanuela Tudorache, Daniel Traila, Ovidiu Fira-Mladinescu, Monica Steluta Marc, Cristian Oancea and Elena Cecilia Rosca
Biomedicines 2024, 12(11), 2572; https://doi.org/10.3390/biomedicines12112572 - 10 Nov 2024
Viewed by 550
Abstract
Patients with interstitial lung diseases (ILDs) associate a large variety of comorbidities that have a significant impact on their clinical outcomes and survival. Among these comorbidities is neurological impairment. This review highlights what is known about the cognitive function, central nervous system (CNS), [...] Read more.
Patients with interstitial lung diseases (ILDs) associate a large variety of comorbidities that have a significant impact on their clinical outcomes and survival. Among these comorbidities is neurological impairment. This review highlights what is known about the cognitive function, central nervous system (CNS), depression, and anxiety in patients with specific forms of fibrosing ILDs, such as idiopathic pulmonary fibrosis, sarcoidosis, hypersensitivity pneumonitis, connective tissue diseases, etc. The most common pathogenic mechanisms for neurocognitive dysfunction as well as the screening methods and tools for their identification are also described in this review. Full article
Show Figures

Figure 1

23 pages, 2659 KiB  
Review
Neurological Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors
by Sotiria Stavropoulou De Lorenzo, Athina Andravizou, Harry Alexopoulos, Iliana Michailidou, Alexandros Bokas, Evangelia Kesidou, Marina-Kleopatra Boziki, Dimitrios Parissis, Christos Bakirtzis and Nikolaos Grigoriadis
Biomedicines 2024, 12(6), 1319; https://doi.org/10.3390/biomedicines12061319 - 13 Jun 2024
Viewed by 1217
Abstract
The use of immune checkpoint inhibitors (ICIs) for the treatment of various advanced and aggressive types of malignancy has significantly increased both survival and long-term remission rates. ICIs block crucial inhibitory pathways of the immune system, in order to trigger an aggravated immune [...] Read more.
The use of immune checkpoint inhibitors (ICIs) for the treatment of various advanced and aggressive types of malignancy has significantly increased both survival and long-term remission rates. ICIs block crucial inhibitory pathways of the immune system, in order to trigger an aggravated immune response against the tumor. However, this enhanced immune activation leads to the development of numerous immune-related adverse events (irAEs), which may affect any system. Although severe neurological irAEs are relatively rare, they carry a high disability burden, and they can be potentially life-threatening. Therefore, clinicians must be alert and act promptly when individuals receiving ICIs present with new-onset neurological symptoms. In this narrative review, we have collected all the currently available data regarding the epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of post-ICI neurological irAEs. This review aims to raise physicians’ awareness, enrich their knowledge regarding disease pathogenesis, and guide them through the diagnosis and management of post-ICI neurological irAEs. Full article
Show Figures

Figure 1

Back to TopTop